These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 11956588)

  • 1. Doxorubicin enhances TRAIL-induced apoptosis in prostate cancer.
    Wu XX; Kakehi Y; Mizutani Y; Kamoto T; Kinoshita H; Isogawa Y; Terachi T; Ogawa O
    Int J Oncol; 2002 May; 20(5):949-54. PubMed ID: 11956588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP.
    Kang J; Bu J; Hao Y; Chen F
    Prostate Cancer Prostatic Dis; 2005; 8(3):274-9. PubMed ID: 15897917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitization of human renal cell carcinoma cell lines to TRAIL-induced apoptosis by anthracyclines.
    Wu XX; Ogawa O; Kakehi Y
    Int J Urol; 2004 Mar; 11(3):164-70. PubMed ID: 15009365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
    Ng CP; Zisman A; Bonavida B
    Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells.
    Munshi A; McDonnell TJ; Meyn RE
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):46-52. PubMed ID: 12111111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
    Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN
    Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis.
    Lacour S; Hammann A; Wotawa A; Corcos L; Solary E; Dimanche-Boitrel MT
    Cancer Res; 2001 Feb; 61(4):1645-51. PubMed ID: 11245478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.
    Voelkel-Johnson C; King DL; Norris JS
    Cancer Gene Ther; 2002 Feb; 9(2):164-72. PubMed ID: 11857034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms.
    Shankar S; Singh TR; Srivastava RK
    Prostate; 2004 Sep; 61(1):35-49. PubMed ID: 15287092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caspase-8 activation is necessary but not sufficient for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in the prostatic carcinoma cell line LNCaP.
    Rokhlin OW; Guseva NV; Tagiyev AF; Glover RA; Cohen MB
    Prostate; 2002 Jun; 52(1):1-11. PubMed ID: 11992615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis.
    Evdokiou A; Bouralexis S; Atkins GJ; Chai F; Hay S; Clayer M; Findlay DM
    Int J Cancer; 2002 Jun; 99(4):491-504. PubMed ID: 11992538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
    Ray S; Almasan A
    Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
    Hotta T; Suzuki H; Nagai S; Yamamoto K; Imakiire A; Takada E; Itoh M; Mizuguchi J
    J Orthop Res; 2003 Sep; 21(5):949-57. PubMed ID: 12919886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment of indole-3-carbinol augments TRAIL-induced apoptosis in a prostate cancer cell line, LNCaP.
    Jeon KI; Rih JK; Kim HJ; Lee YJ; Cho CH; Goldberg ID; Rosen EM; Bae I
    FEBS Lett; 2003 Jun; 544(1-3):246-51. PubMed ID: 12782325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2.
    Munshi A; Pappas G; Honda T; McDonnell TJ; Younes A; Li Y; Meyn RE
    Oncogene; 2001 Jun; 20(29):3757-65. PubMed ID: 11439339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dietary flavonol fisetin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells.
    Szliszka E; Helewski KJ; Mizgala E; Krol W
    Int J Oncol; 2011 Oct; 39(4):771-9. PubMed ID: 21743964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells.
    Yu R; Mandlekar S; Ruben S; Ni J; Kong AN
    Cancer Res; 2000 May; 60(9):2384-9. PubMed ID: 10811114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells.
    Sun SY; Yue P; Lotan R
    Oncogene; 2000 Sep; 19(39):4513-22. PubMed ID: 11002424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells.
    Voelkel-Johnson C
    Cancer Biol Ther; 2003; 2(3):283-90. PubMed ID: 12878867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. eNOS protects prostate cancer cells from TRAIL-induced apoptosis.
    Tong X; Li H
    Cancer Lett; 2004 Jul; 210(1):63-71. PubMed ID: 15172122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.